Better Buy: Ocugen vs. Zomedica
You might not have heard of Ocugen (NASDAQ: OCGN) and Zomedica (NYSEMKT: ZOM) a few months ago. But in recent weeks, their share price performances have prompted investors to sit up and take notice. The stocks have soared more than 450% and 860%, respectively, year to date.
There's a reason for the excitement. Both companies are moving toward the commercialization of a product -- Ocugen in the COVID-19 vaccine space and Zomedica in veterinary diagnostics. At this point, you might be wondering if these stocks represent a buy for the long-term investor -- and which of the two would be the best bet. Let's take a closer look at both of these recent stock market stars.
Image source: Getty Images.
Source Fool.com
